Clal Biotechnology Industries Ltd. (TLV:CBI)
Israel · Delayed Price · Currency is ILS · Price in ILA 27.70
+0.50 (1.84%)
Jun 3, 2026, 5:24 PM IDT
TLV:CBI Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | 0.1 | 0.37 | 0.22 | |
Revenue Growth (YoY) | - | - | -71.89% | 65.18% | 8.74% |
Gross Profit | - | - | 0.1 | 0.37 | 0.22 |
Selling, General & Admin | 4.51 | 6.35 | 9.76 | 12.27 | 12.22 |
Operating Expenses | 4.72 | 6.63 | 10.29 | 12.88 | 12.87 |
Operating Income | -4.72 | -6.63 | -10.18 | -12.51 | -12.65 |
Interest Expense | -0.12 | -3.57 | -3.54 | -3.73 | -1.76 |
Interest & Investment Income | 0.84 | 0.17 | 0.13 | 0.01 | - |
Earnings From Equity Investments | -12.34 | -28.57 | -17 | -22.39 | -30.81 |
Currency Exchange Gain (Loss) | -0.01 | 0.26 | 0.36 | 4.23 | -1.61 |
Other Non Operating Income (Expenses) | -0.07 | -0.74 | -0.86 | -2.31 | 11.38 |
EBT Excluding Unusual Items | -16.42 | -39.07 | -31.09 | -36.69 | -35.44 |
Gain (Loss) on Sale of Investments | -3.75 | -36 | 3 | -8.03 | -31.15 |
Other Unusual Items | - | - | - | 3.7 | - |
Pretax Income | -20.17 | -75.07 | -28.09 | -41.02 | -66.59 |
Earnings From Continuing Operations | -20.17 | -75.07 | -28.09 | -41.02 | -66.59 |
Earnings From Discontinued Operations | - | - | - | -54.41 | -61.63 |
Net Income to Company | -20.17 | -75.07 | -28.09 | -95.43 | -128.21 |
Minority Interest in Earnings | 6.85 | 12.62 | -2.96 | 33.69 | 38.63 |
Net Income | -13.32 | -62.46 | -31.05 | -61.74 | -89.58 |
Net Income to Common | -13.32 | -62.46 | -31.05 | -61.74 | -89.58 |
Shares Outstanding (Basic) | 157 | 157 | 157 | 157 | 158 |
Shares Outstanding (Diluted) | 157 | 157 | 157 | 157 | 158 |
Shares Change (YoY) | - | - | - | -1.01% | -1.74% |
EPS (Basic) | -0.08 | -0.40 | -0.20 | -0.39 | -0.57 |
EPS (Diluted) | -0.09 | -0.40 | -0.20 | -0.39 | -0.57 |
Free Cash Flow | -3.95 | -6.48 | -8.52 | -60.31 | -42.92 |
Free Cash Flow Per Share | -0.03 | -0.04 | -0.05 | -0.39 | -0.27 |
Gross Margin | - | - | 100.00% | 100.00% | 100.00% |
Operating Margin | - | - | -9789.42% | -3380.00% | -5645.09% |
Profit Margin | - | - | -29856.73% | -16686.49% | -39992.41% |
Free Cash Flow Margin | - | - | -8190.39% | -16300.00% | -19160.71% |
EBITDA | -4.51 | -6.35 | -9.66 | 5.14 | 9.87 |
EBITDA Margin | - | - | - | 1388.38% | 4404.46% |
D&A For EBITDA | 0.22 | 0.28 | 0.53 | 17.64 | 22.51 |
EBIT | -4.72 | -6.63 | -10.18 | -12.51 | -12.65 |
Revenue as Reported | 11.55 | 8.57 | 39.73 | 18.03 | 55.26 |